STAT3 is a member of the STAT family of transcription factors and is activated in several cancers including osteosarcoma,8 renal cell carcinoma,9 and pancreatic cancer.10 Inhibition of STAT3 could serve as a potent chemotherapeutic sensitizing strategy to overcome drug resistance in chemoresistant cancer cells.11, 12 However, STAT3 is not an ideal molecular target for cancer therapy, because of its potential damage to normal tissue and other off‐target effects. The gene discussed is STAT3; the disease is cancer.